このページの翻訳は実験的なもので、現在開発中です。お待ちしております

MedPeerInc マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Yo Iwami

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	19.3yrs
CEOの所有権	31.2%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	4.3yrs

経営陣の近況

Recent updates

Market Participants Recognise MedPeer,Inc.'s (TSE:6095) Earnings Pushing Shares 34% Higher

Sep 04

Estimating The Intrinsic Value Of MedPeer,Inc. (TSE:6095)

Aug 02

MedPeerInc's (TSE:6095) Soft Earnings Don't Show The Whole Picture

May 21

CEO（最高経営責任者

Yo Iwami (50 yo)

19.3yrs

在職期間

Dr. Yo Iwami, M.D, Ph D., serves as the President and Representative Director of MedPeer,Inc since June 2005 and serves as its CEO. Dr. Iwami has been an Outside Director of Sogo Rinsho Holdings Co., Ltd....

取締役

名称	ポジション	在職期間	報酬	所有権
Yo Iwami	President	19.3yrs	データなし	31.16% ¥ 3.9b
Naoki Goto	Executive VP & Director	less than a year	データなし	0.0046% ¥ 575.5k
Makoto Haruta	Management Advisor	no data	データなし	データなし
Takashi Hayama	External Auditor	11.8yrs	データなし	0.38% ¥ 47.8m
Hiroyasu Sato	External Auditor	11.8yrs	データなし	データなし
Masatoshi Kawana	Independent Outside Director	4.8yrs	データなし	データなし
Yoshihiko Tembo	Director	3.8yrs	データなし	0.15% ¥ 18.8m
Toshio Hirabayashi	Director	3.8yrs	データなし	0.28% ¥ 35.5m
Mayuko Seto	Independent Outside Director	1.8yrs	データなし	データなし
Masayuki Shimura	Independent Outside Director	1.8yrs	データなし	0.0014% ¥ 172.6k
Shunichi Sueyoshi	Full Time Auditor	6.8yrs	データなし	データなし

4.3yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: 6095の取締役会は経験豊富であると考えられます ( 4年の平均在任期間)。

MedPeerInc マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

MedPeer,Inc., Annual General Meeting, Dec 15, 2022

No independent directors

No independent directors

MedPeer,Inc., Annual General Meeting, Dec 17, 2020

Recent updates

Upcoming dividend of JP¥4.50 per share

Consensus EPS estimates increase by 31%

Market Participants Recognise MedPeer,Inc.'s (TSE:6095) Earnings Pushing Shares 34% Higher

Now 21% overvalued after recent price rise

MedPeer,Inc. to Report Fiscal Year 2024 Results on Nov 13, 2024

Third quarter 2024 earnings released: EPS: JP¥10.59 (vs JP¥1.28 in 3Q 2023)

Investor sentiment deteriorates as stock falls 27%

Estimating The Intrinsic Value Of MedPeer,Inc. (TSE:6095)

MedPeer,Inc. to Report Q3, 2024 Results on Aug 14, 2024

Consensus EPS estimates increase by 11%

Price target decreased by 13% to JP¥725

Consensus EPS estimates fall by 13%

MedPeerInc's (TSE:6095) Soft Earnings Don't Show The Whole Picture

Second quarter 2024 earnings released: JP¥4.15 loss per share (vs JP¥5.02 profit in 2Q 2023)

New minor risk - Market cap size

MedPeer,Inc. to Report Q2, 2024 Results on May 13, 2024

Consensus EPS estimates fall by 19%, revenue upgraded

Investor sentiment improves as stock rises 22%

First quarter 2024 earnings released: EPS: JP¥13.33 (vs JP¥12.40 in 1Q 2023)

New minor risk - Market cap size

Now 21% undervalued after recent price drop

MedPeer,Inc. to Report Q1, 2024 Results on Feb 13, 2024

New minor risk - Market cap size

Now 21% undervalued after recent price drop

Price target decreased by 9.1% to JP¥1,250

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 13%

Now 27% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

New major risk - Share price stability

Now 21% undervalued after recent price drop

MedPeer,Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023

Third quarter 2023 earnings released: EPS: JP¥1.28 (vs JP¥2.59 in 3Q 2022)

MedPeer,Inc. to Report Q3, 2023 Results on Aug 09, 2023

Now 22% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: JP¥5.02 (vs JP¥10.56 in 2Q 2022)

MedPeer,Inc. (TSE:6095) announces an Equity Buyback for 300,000 shares, representing 1.37% for ¥300 million.

Now 24% undervalued after recent price drop

First quarter 2023 earnings released: EPS: JP¥12.40 (vs JP¥17.15 in 1Q 2022)

MedPeer,Inc. (TSE:6095) acquired Business support application series of recruit Medical Career.

Price target decreased to JP¥2,300

MedPeer,Inc. to Report Q1, 2023 Results on Feb 13, 2023

Now 20% undervalued

Now 23% undervalued

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 19%

MedPeer,Inc., Annual General Meeting, Dec 15, 2022

No independent directors

Price target decreased to JP¥2,600

MedPeer,Inc. (TSE:6095) completed the acquisition of Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others.

MedPeer,Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022

Consensus EPS estimates fall by 30%

Consensus EPS estimates fall by 31%

Third quarter 2022 earnings released: EPS: JP¥2.59 (vs JP¥8.03 in 3Q 2021)

MedPeer,Inc. (TSE:6095) entered into an agreement to acquire Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others for ¥5000 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to JP¥3,580

Investor sentiment deteriorated over the past week

MedPeer,Inc. to Report Q3, 2022 Results on Aug 09, 2022

Price target decreased to JP¥4,276

MedPeer,Inc. (TSE:6095) acquired Minkore recently.

Price target decreased to JP¥4,496

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

No independent directors

MedPeer,Inc. to Report Q2, 2022 Results on May 12, 2022

Now 23% undervalued

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

マネジメント基準チェック /14